Eulav Asset Management Exact Sciences Corp Transaction History

Eulav Asset Management

$3.64 Billion
Q1 2024

A detailed history of Eulav Asset Management transactions in Exact Sciences Corp stock. As of the latest transaction made, Eulav Asset Management holds 318,000 shares of EXAS stock, worth $13.4 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

318,000

Previous 257,000 23.74%

Holding current value

$13.4 Million

Previous $19 Million 15.51%

% of portfolio

0.6%

Previous 0.59%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 30, 2024	BUY	$56.27 - $73.77 $3.43 Million - $4.5 Million	61,000 Added 23.74%	318,000 $22 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $1.06 Million - $1.36 Million	18,000 Added 7.53%	257,000 $19 Million
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $923,160 - $1.39 Million	14,000 Added 6.22%	239,000 $16.3 Million
Q2 2023 Aug 09, 2023	SELL	$62.68 - $95.05 $313,400 - $475,250	-5,000 Reduced 2.17%	225,000 $21.1 Million
Q1 2023 Apr 27, 2023	SELL	$47.19 - $70.77 $1.18 Million - $1.77 Million	-25,000 Reduced 9.8%	230,000 $15.6 Million

Q4 2022 Feb 14, 2023	SELL	$30.35 - $53.15 $607,000 - $1.06 Million	-20,000 Reduced 7.27%	255,000 $12.6 Million
Q3 2022 Nov 03, 2022	SELL	$31.97 - $49.37 $319,700 - $493,700	-10,000 Reduced 3.51%	275,000 $8.94 Million
Q2 2022 Jul 22, 2022	SELL	$35.61 - $76.23 $676,590 - $1.45 Million	-19,000 Reduced 6.25%	285,000 $11.2 Million
Q1 2022 May 10, 2022	SELL	$57.56 - $82.54 $4.37 Million - $6.27 Million	-76,000 Reduced 20.0%	304,000 $21.3 Million
Q4 2021 Feb 11, 2022	BUY	$72.5 - $100.68 $3.99 Million - $5.54 Million	55,000 Added 16.92%	380,000 $29.6 Million
Q3 2021 Nov 15, 2021	BUY	$90.24 - $124.05 $10.8 Million - $14.9 Million	120,000 Added 58.54%	325,000 $31 Million
Q2 2021 Aug 06, 2021	BUY	$93.66 - $139.27 $655,620 - $974,890	7,000 Added 3.54%	205,000 $25.5 Million
Q1 2021 Apr 30, 2021	SELL	$116.57 - $155.01 $2.33 Million - $3.1 Million	-20,000 Reduced 9.17%	198,000 $26.1 Million
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $2.49 Million - $3.55 Million	-25,000 Reduced 10.29%	218,000 $28.9 Million
Q3 2020 Nov 05, 2020	BUY	$72.92 - $102.01 $3.57 Million - $5 Million	49,000 Added 25.26%	243,000 $24.8 Million
Q2 2020 Aug 11, 2020	SELL	$55.75 - $92.75 $2.37 Million - $3.94 Million	-42,501 Reduced 17.97%	194,000 $16.9 Million
Q1 2020 Apr 27, 2020	BUY	$37.9 - $104.44 $2.08 Million - $5.74 Million	55,000 Added 30.3%	236,501 $13.7 Million
Q4 2019 Feb 13, 2020	BUY	$77.66 - $99.74 $2.17 Million - $2.79 Million	28,000 Added 18.24%	181,501 $16.8 Million
Q3 2019 Nov 12, 2019	SELL	$90.37 - $122.49 $2.85 Million - $3.86 Million	-31,499 Reduced 17.03%	153,501 $13.9 Million
Q2 2019 Aug 05, 2019	SELL	$89.51 - $118.04 $1.07 Million - $1.42 Million	-12,000 Reduced 6.09%	185,000 $21.8 Million
Q1 2019 May 13, 2019	SELL	$61.98 - $96.5 $1.36 Million - $2.12 Million	-22,000 Reduced 10.05%	197,000 $17.8 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $1.06 Million - $1.57 Million	19,000 Added 9.5%	219,000 $13.8 Million
Q3 2018 Oct 26, 2018	SELL	$48.29 - $80.6 $1.45 Million - $2.42 Million	-30,000 Reduced 13.04%	200,000 $15.8 Million
Q2 2018 Aug 14, 2018	BUY	$37.84 - $69.96 $908,160 - $1.68 Million	24,000 Added 11.65%	230,000 $13.8 Million
Q1 2018 May 09, 2018	BUY	$39.82 - $57.53 $1.23 Million - $1.78 Million	31,000 Added 17.71%	206,000 $8.31 Million
Q4 2017 Feb 14, 2018	SELL	$46.49 - $60.51 $1.86 Million - $2.42 Million	-40,000 Reduced 18.6%	175,000 $9.19 Million
Q3 2017 Nov 14, 2017	SELL	$37.05 - $47.12 $74,100 - $94,240	-2,000 Reduced 0.92%	215,000 $10.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	217,000	217,000 $7.68 Million

Others Institutions Holding EXAS

# of Institutions

699

Shares Held

160M

Call Options Held

5.84M

Put Options Held

2.58M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $7.48B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Eulav Asset Management with notifications on news.

Account

Eulav Asset Management Exact Sciences Corp Transaction History